Symbols / DHR
DHR Chart
About
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 147.88B |
| Enterprise Value | 161.69B | Income | 3.60B | Sales | 24.57B |
| Book/sh | 74.32 | Cash/sh | 6.53 | Dividend Yield | 61.00% |
| Payout | 25.45% | Employees | 60000 | IPO | — |
| P/E | 41.67 | Forward P/E | 22.95 | PEG | — |
| P/S | 6.02 | P/B | 2.81 | P/C | — |
| EV/EBITDA | 22.66 | EV/Sales | 6.58 | Quick Ratio | 1.25 |
| Current Ratio | 1.87 | Debt/Eq | 35.05 | LT Debt/Eq | — |
| EPS (ttm) | 5.02 | EPS next Y | 9.11 | EPS Growth | 12.50% |
| Revenue Growth | 4.60% | Earnings | 2026-04-21 | ROA | 3.64% |
| ROE | 7.05% | ROIC | — | Gross Margin | 59.11% |
| Oper. Margin | 22.17% | Profit Margin | 14.71% | Shs Outstand | 706.90M |
| Shs Float | 629.70M | Short Float | 1.14% | Short Ratio | 1.93 |
| Short Interest | — | 52W High | 242.80 | 52W Low | 171.00 |
| Beta | 0.96 | Avg Volume | 3.84M | Volume | 2.15M |
| Target Price | $264.91 | Recom | Strong_buy | Prev Close | $210.92 |
| Price | $209.19 | Change | -0.82% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$264.91
Mean price target
2. Current target
$209.19
Latest analyst target
3. DCF / Fair value
$109.94
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$209.19
Low
$220.00
High
$310.00
Mean
$264.91
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-29 | main | JP Morgan | Overweight → Overweight | $275 |
| 2026-01-29 | main | Jefferies | Buy → Buy | $265 |
| 2026-01-07 | main | TD Cowen | Buy → Buy | $270 |
| 2026-01-05 | main | Guggenheim | Buy → Buy | $275 |
| 2025-12-15 | main | Wells Fargo | Equal-Weight → Equal-Weight | $240 |
| 2025-12-09 | init | Goldman Sachs | — → Buy | $265 |
| 2025-12-02 | init | Morgan Stanley | — → Overweight | $270 |
| 2025-10-23 | main | Wells Fargo | Equal-Weight → Equal-Weight | $230 |
| 2025-10-22 | main | TD Cowen | Buy → Buy | $260 |
| 2025-10-22 | main | Barclays | Overweight → Overweight | $250 |
| 2025-10-08 | down | Rothschild & Co | Buy → Neutral | $220 |
| 2025-10-07 | main | Evercore ISI Group | Outperform → Outperform | $245 |
| 2025-09-22 | main | B of A Securities | Buy → Buy | $220 |
| 2025-07-23 | main | UBS | Buy → Buy | $225 |
| 2025-07-23 | main | Wells Fargo | Equal-Weight → Equal-Weight | $205 |
| 2025-07-23 | reit | Guggenheim | Buy → Buy | $250 |
| 2025-07-23 | main | Baird | Outperform → Outperform | $229 |
| 2025-07-18 | main | Baird | Outperform → Outperform | $226 |
| 2025-07-11 | up | Scotiabank | Sector Perform → Sector Outperform | $275 |
| 2025-07-08 | main | Evercore ISI Group | Outperform → Outperform | $226 |
News
RSS: Latest DHR news- Danaher to pay shareholders $0.40 per share in April dividend - Stock Titan ue, 24 Feb 2026 21
- Danaher (DHR) is Gaining from Improvement in Its Bioprocessing Business - Yahoo Finance Singapore ue, 24 Feb 2026 13
- All-Cash Masimo Deal Offers Strong Strategic Fit For Danaher Corporation (DHR) - Finviz ue, 24 Feb 2026 20
- Danaher Corporation $DHR Stock Position Trimmed by LaFleur & Godfrey LLC - MarketBeat Mon, 23 Feb 2026 11
- Danaher (DHR) Boosts Dividend by 25% to $0.40 per Share - GuruFocus Wed, 25 Feb 2026 03
- Danaher stock drops after Q4 2025 results (DHR:NYSE) - Seeking Alpha Wed, 28 Jan 2026 08
- Danaher Masimo Deal Reshapes Patient Monitoring And Diagnostics Exposure - simplywall.st ue, 24 Feb 2026 15
- Understanding the Setup: (DHR) and Scalable Risk - Stock Traders Daily Sun, 22 Feb 2026 08
- First Financial Bankshares Inc Raises Stock Holdings in Danaher Corporation $DHR - MarketBeat ue, 24 Feb 2026 12
- Masimo stock surges on $180 per share Danaher acquisition deal (DHR:NYSE) - Seeking Alpha ue, 17 Feb 2026 13
- Do Wall Street Analysts Like Danaher Stock? - Yahoo Finance Wed, 11 Feb 2026 08
- CenterBook Partners LP Reduces Stock Holdings in Danaher Corporation $DHR - MarketBeat Sun, 22 Feb 2026 08
- Danaher Corp. (DHR) Signaled Signs of a Stable Bioprocessing Segment - Yahoo Finance ue, 17 Feb 2026 16
- Payden & Rygel Lowers Stock Position in Danaher Corporation $DHR - MarketBeat Mon, 23 Feb 2026 12
- Zeno Equity Partners LLP Buys 6,856 Shares of Danaher Corporation $DHR - MarketBeat Sun, 22 Feb 2026 13
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1320 | 274575 | — | Sale at price 208.01 per share. | MILOSEVICH GREGORY M | Officer | — | 2026-02-19 00:00:00 | D |
| 1 | 1320 | 77339 | — | Conversion of Exercise of derivative security at price 58.59 per share. | MILOSEVICH GREGORY M | Officer | — | 2026-02-19 00:00:00 | D |
| 2 | 1046 | — | — | Stock Award(Grant) at price 0.00 per share. | RILEY CHRISTOPHER PAUL | Officer | — | 2026-02-04 00:00:00 | D |
| 3 | 848 | — | — | Stock Award(Grant) at price 0.00 per share. | SAWYER MONTGOMERY JULIE A | Officer | — | 2026-02-04 00:00:00 | D |
| 4 | 679 | — | — | Stock Award(Grant) at price 0.00 per share. | MILOSEVICH GREGORY M | Officer | — | 2026-02-04 00:00:00 | D |
| 5 | 1695 | — | — | Stock Award(Grant) at price 0.00 per share. | ELLIS BRIAN W | Officer | — | 2026-02-04 00:00:00 | D |
| 6 | 8474 | — | — | Stock Award(Grant) at price 0.00 per share. | BLAIR RAINER M | Chief Executive Officer | — | 2026-02-04 00:00:00 | D |
| 7 | 1695 | — | — | Stock Award(Grant) at price 0.00 per share. | GUTIERREZ-RAMOS JOSE-CARLOS | Officer | — | 2026-02-04 00:00:00 | D |
| 8 | 2684 | — | — | Stock Award(Grant) at price 0.00 per share. | MCGREW MATTHEW | Chief Financial Officer | — | 2026-02-04 00:00:00 | D |
| 9 | 1413 | — | — | Stock Award(Grant) at price 0.00 per share. | COUCHARA GEORGEANN F. | Officer | — | 2026-02-04 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -9.18M | -29.67M | -30.89M | 48.90M |
| TaxRateForCalcs | 0.16 | 0.16 | 0.11 | 0.16 |
| NormalizedEBITDA | 7.33B | 7.68B | 9.75B | 8.50B |
| TotalUnusualItems | -57.00M | -182.00M | -271.00M | 300.00M |
| TotalUnusualItemsExcludingGoodwill | -57.00M | -182.00M | -271.00M | 300.00M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 3.90B | 4.22B | 6.33B | 5.45B |
| ReconciledDepreciation | 2.35B | 2.17B | 2.13B | 2.06B |
| ReconciledCostOfRevenue | 9.67B | 9.86B | 10.46B | 9.56B |
| EBITDA | 7.28B | 7.50B | 9.48B | 8.80B |
| EBIT | 4.92B | 5.33B | 7.35B | 6.74B |
| NetInterestIncome | -161.00M | 17.00M | -163.00M | -220.00M |
| InterestExpense | 278.00M | 286.00M | 204.00M | 231.00M |
| InterestIncome | 117.00M | 303.00M | 41.00M | 11.00M |
| NormalizedIncome | 3.95B | 4.37B | 6.57B | 5.20B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 3.90B | 4.76B | 7.21B | 6.43B |
| TotalExpenses | 19.01B | 18.69B | 19.11B | 18.41B |
| TotalOperatingIncomeAsReported | 4.86B | 5.20B | 7.54B | 6.38B |
| DilutedAverageShares | 716.10M | 737.20M | 743.10M | 737.10M |
| BasicAverageShares | 712.70M | 731.00M | 736.50M | 725.10M |
| DilutedEPS | 5.05 | 5.29 | 6.38 | 9.66 |
| BasicEPS | 5.07 | 5.33 | 6.44 | 9.80 |
| DilutedNIAvailtoComStockholders | 3.90B | 4.74B | 7.10B | 6.27B |
| NetIncomeCommonStockholders | 3.90B | 4.74B | 7.10B | 6.27B |
| PreferredStockDividends | 21.00M | 106.00M | 164.00M | |
| NetIncome | 3.90B | 4.76B | 7.21B | 6.43B |
| NetIncomeIncludingNoncontrollingInterests | 3.90B | 4.76B | 7.21B | 6.43B |
| NetIncomeDiscontinuousOperations | 0.00 | 543.00M | 881.00M | 986.00M |
| NetIncomeContinuousOperations | 3.90B | 4.22B | 6.33B | 5.45B |
| TaxProvision | 747.00M | 823.00M | 818.00M | 1.06B |
| PretaxIncome | 4.65B | 5.04B | 7.15B | 6.51B |
| OtherIncomeExpense | -56.00M | -175.00M | -227.00M | 344.00M |
| OtherNonOperatingIncomeExpenses | 1.00M | 7.00M | 44.00M | 44.00M |
| SpecialIncomeCharges | -108.00M | 0.00 | -101.00M | |
| GainOnSaleOfBusiness | 0.00 | 0.00 | 5.00M | |
| OtherSpecialCharges | 96.00M | |||
| WriteOff | 108.00M | 91.00M | 10.00M | |
| GainOnSaleOfSecurity | -57.00M | -182.00M | -271.00M | 401.00M |
| NetNonOperatingInterestIncomeExpense | -161.00M | 17.00M | -163.00M | -220.00M |
| InterestExpenseNonOperating | 278.00M | 286.00M | 204.00M | 231.00M |
| InterestIncomeNonOperating | 117.00M | 303.00M | 41.00M | 11.00M |
| OperatingIncome | 4.86B | 5.20B | 7.54B | 6.39B |
| OperatingExpense | 9.34B | 8.83B | 8.65B | 8.85B |
| OtherOperatingExpenses | 547.00M | |||
| ResearchAndDevelopment | 1.58B | 1.50B | 1.53B | 1.50B |
| SellingGeneralAndAdministration | 7.76B | 7.33B | 7.12B | 6.81B |
| GrossProfit | 14.21B | 14.03B | 16.19B | 15.24B |
| CostOfRevenue | 9.67B | 9.86B | 10.46B | 9.56B |
| TotalRevenue | 23.88B | 23.89B | 26.64B | 24.80B |
| OperatingRevenue | 23.88B | 23.89B | 26.64B | 24.80B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 165.20M | 141.30M | 141.00M | 140.70M |
| PreferredSharesNumber | 1.72M | 1.72M | 1.72M | 3.37M |
| OrdinarySharesNumber | 719.10M | 739.20M | 728.30M | 715.00M |
| ShareIssued | 884.30M | 880.50M | 869.30M | 855.70M |
| NetDebt | 13.93B | 12.54B | 13.68B | 19.59B |
| TotalDebt | 17.15B | 19.54B | 20.62B | 23.27B |
| TangibleBookValue | -9.52B | -8.87B | -8.68B | -22.13B |
| InvestedCapital | 65.55B | 71.89B | 68.09B | 64.08B |
| WorkingCapital | 2.70B | 5.66B | 7.49B | 3.51B |
| NetTangibleAssets | -9.52B | -8.87B | -7.01B | -18.86B |
| CapitalLeaseObligations | 1.14B | 1.13B | 939.00M | 1.10B |
| CommonStockEquity | 49.54B | 53.49B | 48.41B | 41.90B |
| PreferredStockEquity | 1.67B | 3.27B | ||
| TotalCapitalization | 65.04B | 70.19B | 69.17B | 67.33B |
| TotalEquityGrossMinorityInterest | 49.55B | 53.49B | 50.09B | 45.18B |
| MinorityInterest | 7.00M | 4.00M | 8.00M | 10.00M |
| StockholdersEquity | 49.54B | 53.49B | 50.08B | 45.17B |
| GainsLossesNotAffectingRetainedEarnings | -3.22B | -1.75B | -2.87B | -1.03B |
| OtherEquityAdjustments | -3.22B | -1.75B | -2.87B | -1.03B |
| TreasuryStock | 8.16B | 2.02B | ||
| RetainedEarnings | 44.19B | 41.07B | 39.20B | 32.83B |
| AdditionalPaidInCapital | 16.73B | 16.17B | 12.07B | 10.09B |
| CapitalStock | 9.00M | 9.00M | 1.68B | 3.28B |
| CommonStock | 9.00M | 9.00M | 9.00M | 9.00M |
| PreferredStock | 0.00 | 0.00 | 1.67B | 3.27B |
| TotalLiabilitiesNetMinorityInterest | 27.99B | 31.00B | 34.26B | 38.01B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 21.19B | 22.72B | 25.87B | 29.87B |
| OtherNonCurrentLiabilities | 214.00M | 228.00M | 261.00M | 219.00M |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 287.00M | ||
| EmployeeBenefits | 849.00M | 798.00M | 690.00M | 1.15B |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 560.00M | 544.00M | 492.00M | 876.00M |
| TradeandOtherPayablesNonCurrent | 3.42B | 3.78B | 4.55B | 5.23B |
| NonCurrentDeferredLiabilities | 232.00M | 249.00M | 221.00M | 213.00M |
| NonCurrentDeferredRevenue | 232.00M | 249.00M | 221.00M | 213.00M |
| LongTermDebtAndCapitalLeaseObligation | 16.47B | 17.66B | 19.86B | 23.06B |
| LongTermCapitalLeaseObligation | 968.00M | 954.00M | 772.00M | 889.00M |
| LongTermDebt | 15.50B | 16.71B | 19.09B | 22.17B |
| LongTermProvisions | 6.00M | 6.00M | 6.00M | 2.00M |
| CurrentLiabilities | 6.80B | 8.27B | 8.39B | 8.14B |
| OtherCurrentLiabilities | 1.08B | 1.17B | 2.23B | 1.30B |
| CurrentDeferredLiabilities | 1.30B | 1.47B | 1.46B | 1.61B |
| CurrentDeferredRevenue | 1.30B | 1.47B | 1.46B | 1.61B |
| CurrentDebtAndCapitalLeaseObligation | 678.00M | 1.88B | 758.00M | 215.00M |
| CurrentCapitalLeaseObligation | 173.00M | 180.00M | 167.00M | 207.00M |
| CurrentDebt | 505.00M | 1.70B | 591.00M | 8.00M |
| OtherCurrentBorrowings | 505.00M | 1.70B | 591.00M | 8.00M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.16B | 1.18B | 1.22B | 1.44B |
| CurrentProvisions | 185.00M | 155.00M | 171.00M | 221.00M |
| PayablesAndAccruedExpenses | 2.40B | 2.42B | 2.55B | 3.35B |
| Payables | 2.40B | 2.42B | 2.55B | 3.35B |
| OtherPayable | 75.00M | 75.00M | 75.00M | 75.00M |
| TotalTaxPayable | 568.00M | 582.00M | 621.00M | 707.00M |
| AccountsPayable | 1.75B | 1.77B | 1.86B | 2.57B |
| TotalAssets | 77.54B | 84.49B | 84.35B | 83.18B |
| TotalNonCurrentAssets | 68.05B | 70.55B | 68.47B | 71.54B |
| OtherNonCurrentAssets | 3.99B | 3.64B | 7.66B | 3.72B |
| GoodwillAndOtherIntangibleAssets | 59.06B | 62.35B | 57.10B | 64.03B |
| OtherIntangibleAssets | 18.57B | 20.75B | 19.82B | 22.84B |
| Goodwill | 40.50B | 41.61B | 37.28B | 41.18B |
| NetPPE | 4.99B | 4.55B | 3.71B | 3.79B |
| AccumulatedDepreciation | -4.10B | -3.83B | -3.43B | -3.46B |
| GrossPPE | 9.09B | 8.38B | 7.14B | 7.25B |
| OtherProperties | 1.88B | 1.79B | 1.67B | 1.77B |
| MachineryFurnitureEquipment | 4.43B | 4.11B | 3.48B | 3.61B |
| BuildingsAndImprovements | 2.55B | 2.27B | 1.79B | 1.68B |
| LandAndImprovements | 230.00M | 210.00M | 201.00M | 203.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 9.50B | 13.94B | 15.88B | 11.65B |
| OtherCurrentAssets | 1.55B | 1.56B | 1.74B | 1.66B |
| AssetsHeldForSaleCurrent | 0.00 | 1.28B | ||
| PrepaidAssets | 1.66B | |||
| Inventory | 2.33B | 2.59B | 2.77B | 2.77B |
| FinishedGoods | 1.15B | 1.28B | 1.36B | 1.34B |
| WorkInProcess | 465.00M | 459.00M | 422.00M | 473.00M |
| RawMaterials | 720.00M | 853.00M | 984.00M | 951.00M |
| Receivables | 3.54B | 3.92B | 4.10B | 4.63B |
| AccountsReceivable | 3.54B | 3.92B | 4.10B | 4.63B |
| AllowanceForDoubtfulAccountsReceivable | -113.00M | -120.00M | -92.00M | -124.00M |
| GrossAccountsReceivable | 3.65B | 4.04B | 4.19B | 4.75B |
| CashCashEquivalentsAndShortTermInvestments | 2.08B | 5.86B | 6.00B | 2.59B |
| CashAndCashEquivalents | 2.08B | 5.86B | 6.00B | 2.59B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 5.30B | 5.78B | 7.40B | 7.12B |
| RepurchaseOfCapitalStock | -5.98B | 0.00 | 0.00 | 0.00 |
| RepaymentOfDebt | -1.67B | -620.00M | -965.00M | -1.28B |
| IssuanceOfDebt | 0.00 | 0.00 | 984.00M | |
| IssuanceOfCapitalStock | 162.00M | 68.00M | 31.00M | 86.00M |
| CapitalExpenditure | -1.39B | -1.38B | -1.12B | -1.24B |
| EndCashPosition | 2.08B | 5.86B | 6.00B | 2.59B |
| BeginningCashPosition | 5.86B | 6.00B | 2.59B | 6.04B |
| EffectOfExchangeRateChanges | -108.00M | 59.00M | -306.00M | -115.00M |
| ChangesInCash | -3.68B | -190.00M | 3.71B | -3.33B |
| FinancingCashFlow | -8.38B | -273.00M | -2.57B | 1.29B |
| CashFlowFromContinuingFinancingActivities | -8.38B | -273.00M | -2.57B | 1.29B |
| NetOtherFinancingCharges | -131.00M | 2.53B | -95.00M | -16.00M |
| CashDividendsPaid | -768.00M | -1.25B | -818.00M | -742.00M |
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | -5.82B | 68.00M | 31.00M | 86.00M |
| CommonStockPayments | -5.98B | 0.00 | 0.00 | 0.00 |
| CommonStockIssuance | 162.00M | 68.00M | 31.00M | 86.00M |
| NetIssuancePaymentsOfDebt | -1.67B | -1.63B | -1.69B | 1.97B |
| NetShortTermDebtIssuance | 5.00M | -1.01B | -723.00M | 2.27B |
| NetLongTermDebtIssuance | -1.67B | -620.00M | -965.00M | -298.00M |
| LongTermDebtPayments | -1.67B | -620.00M | -965.00M | -1.28B |
| LongTermDebtIssuance | 0.00 | 0.00 | 984.00M | |
| InvestingCashFlow | -1.98B | -7.08B | -2.23B | -12.99B |
| CashFromDiscontinuedInvestingActivities | 0.00 | -33.00M | -89.00M | -97.00M |
| CashFlowFromContinuingInvestingActivities | -1.98B | -7.05B | -2.15B | -12.89B |
| NetOtherInvestingChanges | 34.00M | 44.00M | 51.00M | 37.00M |
| NetInvestmentPurchaseAndSale | -78.00M | -111.00M | -505.00M | -799.00M |
| SaleOfInvestment | 253.00M | 61.00M | 18.00M | 126.00M |
| PurchaseOfInvestment | -331.00M | -172.00M | -523.00M | -925.00M |
| NetBusinessPurchaseAndSale | -558.00M | -5.61B | -582.00M | -10.90B |
| SaleOfBusiness | 0.00 | 26.00M | ||
| PurchaseOfBusiness | -558.00M | -5.61B | -582.00M | -10.90B |
| NetPPEPurchaseAndSale | -1.38B | -1.37B | -1.11B | -1.23B |
| SaleOfPPE | 13.00M | 12.00M | 9.00M | 13.00M |
| PurchaseOfPPE | -1.39B | -1.38B | -1.12B | -1.24B |
| OperatingCashFlow | 6.69B | 7.16B | 8.52B | 8.36B |
| CashFromDiscontinuedOperatingActivities | 0.00 | 674.00M | 906.00M | 935.00M |
| CashFlowFromContinuingOperatingActivities | 6.69B | 6.49B | 7.61B | 7.42B |
| ChangeInWorkingCapital | -198.00M | -470.00M | -1.41B | -561.00M |
| ChangeInOtherWorkingCapital | -483.00M | -1.20B | -582.00M | -102.00M |
| ChangeInPayablesAndAccruedExpense | -467.00M | -192.00M | 79.00M | 548.00M |
| ChangeInAccruedExpense | -486.00M | -43.00M | 97.00M | 64.00M |
| ChangeInPayable | 19.00M | -149.00M | -18.00M | 484.00M |
| ChangeInAccountPayable | 19.00M | -149.00M | -18.00M | 484.00M |
| ChangeInPrepaidAssets | 274.00M | 419.00M | -73.00M | 17.00M |
| ChangeInInventory | 147.00M | 185.00M | -448.00M | -427.00M |
| ChangeInReceivables | 331.00M | 322.00M | -389.00M | -597.00M |
| ChangesInAccountReceivables | 331.00M | 322.00M | -389.00M | -597.00M |
| OtherNonCashItems | 25.00M | 8.00M | 601.00M | |
| StockBasedCompensation | 288.00M | 306.00M | 295.00M | 184.00M |
| AssetImpairmentCharge | 265.00M | 77.00M | 0.00 | |
| DepreciationAmortizationDepletion | 2.35B | 2.17B | 2.13B | 2.06B |
| DepreciationAndAmortization | 2.35B | 2.17B | 2.13B | 2.06B |
| AmortizationCashFlow | 1.63B | 1.49B | 1.43B | 1.39B |
| AmortizationOfIntangibles | 1.63B | 1.49B | 1.43B | 1.39B |
| Depreciation | 721.00M | 675.00M | 698.00M | 674.00M |
| OperatingGainsLosses | 57.00M | 182.00M | 271.00M | -310.00M |
| GainLossOnInvestmentSecurities | 57.00M | 182.00M | 271.00M | |
| GainLossOnSaleOfBusiness | 182.00M | 271.00M | -406.00M | |
| NetIncomeFromContinuingOperations | 3.90B | 4.22B | 6.33B | 5.45B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for DHR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|